Can Finerenone Alter Glomerular Disease Trajectory? - Summary - MDSpire
Advertisement
Can Finerenone Alter Glomerular Disease Trajectory?
A prespecified exploratory analysis of the FIND-CKD clinical trial examined kidney function, albuminuria, and kidney failure outcomes in 903 patients with glomerular diseases.
To explore renal outcomes in patients with glomerular disease receiving finerenone compared to placebo in a randomized, double-blind trial.
Key Findings:
eGFR decline was −3.50 mL/min/1.73 m² per year with finerenone vs −4.23 mL/min/1.73 m² per year with placebo, indicating a significant difference.
Kidney failure or sustained eGFR decline occurred at rates of 7.42 vs 9.60 events per 100 patient-years for finerenone and placebo, respectively.
Finerenone reduced urinary albumin-to-creatinine ratio by 47% in the immunoglobulin A nephropathy subgroup.
Serious adverse events occurred in 20% of finerenone and 21% of placebo participants.
Interpretation:
Finerenone may attenuate chronic eGFR decline in patients with glomerular diseases, particularly in those with immunoglobulin A nephropathy.
Limitations:
The analysis was exploratory and not powered for time-to-event outcomes.
Kidney disease etiology was based on investigator-reported diagnoses, with limited biopsy confirmation, which may affect the reliability of the findings.
Exclusion of patients receiving immunosuppressive therapy may limit generalizability of the results.
Conclusion:
Finerenone shows potential in altering the trajectory of glomerular disease, particularly in immunoglobulin A nephropathy, but further studies are needed to confirm these findings.
